This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Vir Biotech, Glaxo Begin Phase III Study on Coronavirus Therapy
by Zacks Equity Research
Vir Biotechnology (VIR) and British partner Glaxo announce the global expansion of their COMET-ICE study on the COVID-19 antibody candidate VIR-7831 to phase III.
4 Top ETFs, Stocks From Attractive Sectors Pre Q3 Earnings
by Sweta Killa
We have highlighted one ETF and one stock from the four sectors that could make great plays as the earnings season unfolds.
Current Outlook Gloomy
by Zacks Equity Research
Current Outlook Gloomy
A Murky Way Forward, Plus Lilly's New Candidate
by Mark Vickery
There is plenty to address in the coming weeks and months, though not much will be moving the needle this morning.
DICK'S, Las Vegas Sands, Regeneron, Gilead and Eli Lilly as Zacks Bull and Bear of the Day
by Zacks Equity Research
DICK'S, Las Vegas Sands, Regeneron, Gilead and Eli Lilly as Zacks Bull and Bear of the Day
Eli Lilly (LLY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Eli Lilly (LLY) closed at $146.63, marking a +0.98% move from the previous day.
Regeneron, Gilead in Focus as Trump Tests COVID-19 Positive
by Zacks Equity Research
The biotech companies experimenting coronavirus treatments are in greater focus now as President Trump test COVID-19 positive.
Sanofi's MAA for Pompe Disease Candidate Gets EMA's Acceptance
by Zacks Equity Research
The European Medicines Agency accepts for review Sanofi's (SNY) marketing authorization application for avalglucosidase alfa as a long-term enzyme replacement therapy for treating Pompe disease.
Why Lilly (LLY) Could Beat Earnings Estimates Again
by Zacks Equity Research
Lilly (LLY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Know These 3 Facts to Avoid Paying Half Your Retirement Income to the IRS - October 01, 2020
by Zacks Equity Research
Like the majority of investors, you're most likely working on a retirement portfolio that will provide a large enough nest egg to give you a comfortable retirement. Make sure you know all about what financial planners call the accumulation and distribution phases of retirement planning.
3 Reasons Growth Investors Will Love Lilly (LLY)
by Zacks Equity Research
Lilly (LLY) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Why Eli Lilly (LLY) is a Top Dividend Stock for Your Portfolio
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.
Is Eli Lilly and (LLY) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (LLY) Outperforming Other Medical Stocks This Year?
Pfizer's (PFE) Xeljanz Gets FDA Approval for 4th Indication
by Zacks Equity Research
Pfizer's (PFE) Xeljanz gets approval for children and adolescents 2 years and older with active polyarticular course juvenile idiopathic arthritis (pcJIA).
Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed at $148.10 in the latest trading session, marking a -1.44% move from the prior day.
Gilead & Galapagos' RA Drug Receives Approval in Europe
by Zacks Equity Research
Gilead (GILD) and partner Galapagos win approval for their rheumatoid arthritis (RA) drug in Europe.
Galapagos Gets First Commercial Drug With Jyseleca Approval
by Zacks Equity Research
Galapagos (GLPG) and Gilead announce approval of Jyseleca in Europe as a treatment for rheumatoid arthritis patients.
Gilead's Rheumatoid Arthritis Drug Gets Approval in Japan
by Zacks Equity Research
Gilead's (GILD) rheumatoid arthritis drug, Jyseleca, wins approval in Japan.
4 Reasons to Bet on Small-Cap ETFs Now
by Sanghamitra Saha
Small-cap stocks were hurt badly during the peak of the coronavirus-led lockdowns. Now, the gradual uptick of reopening trade has started to favor the small-cap spectrum.
Pharma Stock Roundup: J&J's Coronavirus Vaccine in Phase III, Other Updates
by Kinjel Shah
J&J (JNJ) becomes the fourth company to start a phase III study on its coronavirus vaccine candidate. CHMP recommends approval of several drugs.
RedHill Gets Nod in Brazil for Coronavirus Study on Opaganib
by Zacks Equity Research
The Brazilian Health Regulatory Agency okays RedHill's (RDHL) to conduct a phase II/III study on opaganib for treating patients with severe COVID-19 infection and pneumonia. Stock up.
Eli Lilly (LLY) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Eli Lilly (LLY) closed at $151.18, marking a -1.94% move from the previous day.
Lilly's Olumiant Gets CHMP Nod for Eczema Label Expansion
by Zacks Equity Research
Eli Lilly's (LLY) label expansion application for Olumiant to include atopic dermatitis in Europe patients gets CHMP recommendation for approval in Europe.
Sorrento Gets FDA Nod for Phase I Study on Coronavirus Antibody
by Zacks Equity Research
Sorrento (SRNE) receives an FDA clearance to begin a phase I study on STI-1499 (COVI-GUARD) for treating hospitalized COVID-19 patients. Shares rise.
Lilly, Amgen Ink Manufacturing Deal for Coronavirus Antibodies
by Zacks Equity Research
Eli Lilly (LLY) is developing several potential neutralizing antibodies to treat COVID-19.